Live Analyst Rating Changes 8322 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kambiz Yazdi
BTIG
Kambiz Yazdi
BTIG
Wall Street Analyst
★★★☆☆
#1003
on 13Foresight · ranked by our own returns
68%
Success Rate
+20.4%
Average Return
13 of 19 calls profitable · +13.2% vs benchmark
📈 Across the calls we could measure, roughly 68% of Kambiz Yazdi's ratings turned a profit when each position was held for 1 year — averaging +20.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

41 Buy 0 Hold 0 Sell
Kambiz's Stock Coverage 15 ratings · 2026-07-15
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
KZIA
Kazia Therapeutics
 Jul 01, 2026 BUY Strong Buy
+83.8% avg upside
7 analysts
$34.00
152.38% Upside
 +1.5%
ABSI
AbSci
 Jul 01, 2026 BUY Strong Buy
+18.2% avg upside
18 analysts
$13.00
27.06% Upside
 -9.2%
ZVRA
Zevra Therapeutics
 Jul 01, 2026 BUY Strong Buy
+82.4% avg upside
15 analysts
$27.00
106.72% Upside
 -8.0%
PRAX
Praxis Precision Medicines
 Jun 29, 2026 BUY Strong Buy
+62.8% avg upside
24 analysts
$810.00
147.17% Upside
 -8.9%
RAPP
Rapport Therapeutics, Inc.
 Jun 01, 2026 BUY Strong Buy
+31.8% avg upside
13 analysts
$65.00
56.82% Upside
 +8.6%
VTVT
vTv Therapeutics
 May 13, 2026 BUY Strong Buy
+11.2% avg upside
13 analysts
$49.00
53.77% Upside
 +6.6%
SION
Sionna Therapeutics, Inc.
 May 12, 2026 BUY Strong Buy
+25.5% avg upside
11 analysts
$58.00
36.26% Upside
 +7.5%
ES:PHM
Pharma Mar SA
 Apr 23, 2026 BUY Strong Buy
+43.7% avg upside
4 analysts
$121.00
58.76% Upside
 ·
ARQT
Arcutis Biotherapeutics
 Jan 15, 2026 BUY Strong Buy
+46.2% avg upside
14 analysts
$31.00
15.62% Upside
 +1.7%
LQDA
Liquidia Technologies
 May 28, 2025 BUY Strong Buy
-25.6% avg upside
15 analysts
$31.00
59.40% Downside
 +337.4%
AVTX
Avalo Therapeutics
 Mar 25, 2025 BUY Strong Buy
+184.3% avg upside
20 analysts
$23.00
24.96% Upside
 +63.3%
EYPT
EyePoint Pharmaceuticals
 Aug 28, 2024 BUY Strong Buy
+138.8% avg upside
19 analysts
$15.00
9.22% Upside
 +31.5%
PMVP
PMV Pharmaceuticals
 Apr 11, 2024 BUY Strong Buy
+951.8% avg upside
12 analysts
$5.00
252.13% Upside
 -44.9%
HOWL
Werewolf Therapeutics
 Mar 07, 2024 BUY Strong Buy
+1917.4% avg upside
8 analysts
$14.00
3968.61% Upside
 -81.8%
CARM
Carisma Therapeutics
 May 31, 2023 BUY Buy
+56150.0% avg upside
11 analysts
$7.00
134515.48% Upside
 -76.5%
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kambiz Yazdi — Frequently Asked Questions
How accurate are Kambiz Yazdi's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Kambiz's ratings were profitable over a one-year hold, with an average return of +22.2% per rating, or +14.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Kambiz ranked on 13Foresight?
Kambiz Yazdi is currently ranked #1003 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kambiz cover?
Kambiz most recently has ratings on KZIA, ABSI, ZVRA, PRAX, RAPP, VTVT, SION, ES:PHM, ARQT, LQDA, AVTX, EYPT and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.